Page last updated: 2024-08-24

gemcitabine and piroxicam

gemcitabine has been researched along with piroxicam in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jeglum, AK; Lindner, D; Marconato, L; Nelson, V; Suslak-Brown, L; Zini, E1

Reviews

1 review(s) available for gemcitabine and piroxicam

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for gemcitabine and piroxicam

ArticleYear
Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.
    Journal of the American Veterinary Medical Association, 2011, Apr-15, Volume: 238, Issue:8

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Gemcitabine; Male; Piroxicam; Urinary Bladder Neoplasms

2011

Other Studies

1 other study(ies) available for gemcitabine and piroxicam

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004